seanc
I do not consider the Phase 3 Lavender study in Rett Syndrome to be a "dubious source" as indicated by you.The results of this study are widely available and not just from the Retts Syndrome Research Trust.Hottod even quoted in the above post that " the results you have provided were the Lavender CGI-I (physician rated) results".
These results were the basis tor the approval of Trofinetide by the FDA and physicians indicated that at 12 weeks 62% of patients showed no improvement.Apart from the obvious patient improvement perspective -a lack of patient improvement can have an impact on discontinuations as well as insurance reauthorisations.
That is about as polite as I can be here.
Kens
Share Price, page-10865
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |